Distributed facility for fragment based drug discovery

  • Scanlon, Martin (Primary Chief Investigator (PCI))
  • Dixon, Nicholas (Chief Investigator (CI))
  • Gooley, Paul (Chief Investigator (CI))
  • Hughes, Richard Anthony (Chief Investigator (CI))
  • Kwan, Ann (Chief Investigator (CI))
  • Lewis, Peter (Chief Investigator (CI))
  • Mackay, Joel (Chief Investigator (CI))
  • Matthews, Jacqueline (Chief Investigator (CI))
  • Norton, Raymond (Chief Investigator (CI))
  • Oakley, Aaron J. (Chief Investigator (CI))
  • Scammells, Peter (Chief Investigator (CI))

Project: Research

Project Description

There is an unmet need for the capacity to generate small molecules that modulate therapeutically and
biologically important protein targets.
Fragment-based drug design (FBDD) provides a rational approach to generate such biologically active
compounds.
The Distributed FBDD Facility will provide a mechanism for researchers throughout Australia to access the
necessary infrastructure to undertake FBDD projects against a range of biologically important targets. The facility
will enable access to high-throughput NMR spectroscopy and surface plasmon resonance, it will generate the
capacity for automation in chemical synthesis and sample preparation to expedite the development of novel
bioactive molecules.
StatusFinished
Effective start/end date1/01/1627/09/16

Funding

  • Australian Research Council (ARC): AUD380,000.00
  • Monash University: AUD115,468.00
  • Monash University: AUD57,734.00
  • The University of Sydney: AUD173,203.00
  • University of Wollongong: AUD12,990.00
  • The University of Newcastle: AUD25,980.00
  • The University of Melbourne: AUD17,320.00